Long-term safety of continuous levodopa/carbidopa infusion with ND0612: Results from the ongoing BeyoND study

Background:ND0612 is in development as a continuous, subcutaneous levodopa/carbidopa (LD/CD) delivery system for Parkinson’s disease (PD) experiencing motor fluctuations. Primary safety data from the BeyoND study (NCT02726386) showed that subcutaneous LD/CD infusion with ND0612 is generally safe up to one year of treatment. The study has been extended to 102 months, and we report cumulative data beyond the first year of treatment.